GH secretagogue

CJC-1295 with DAC

Also known as DAC:GRF

Longer-acting GH support for people who want fewer injections.

Emerging evidence

Overview

CJC-1295 with DAC is a modified GHRH analog that includes a drug affinity complex (DAC) - a molecular addition that binds the peptide to albumin in the bloodstream and keeps it active for several days per dose. This gives it a fundamentally different profile from the no-DAC version: instead of producing sharp, short-lived GH pulses, it raises the overall GH baseline for an extended period. That longer-acting profile makes it attractive for people who want fewer injections while still supporting muscle building, recovery, and longevity goals. Fat loss is a secondary benefit. It is an option for those with compliance concerns around daily dosing. CJC-1295 with DAC is given as a subcutaneous injection of 1-2 mg, once or twice per week, on a consistent day. The timing is flexible - it does not need to be taken on an empty stomach the way shorter-acting GHRH analogs do. Courses typically run three to six months. The main caution is that raising the GH baseline continuously is physiologically different from preserving natural pulses, and water retention is possible. As with all GH secretagogues, it is contraindicated in anyone with a cancer history. It should not be combined with MK-677 or with CJC-1295 (no DAC). It pairs well with ipamorelin. CJC-1295 with DAC is available through compounding pharmacies in the US and carries an emerging evidence base - meaning the data supporting it is promising but less established than for fully clinical-grade peptides. Your licensed provider in the PepDepo network will review your goals and history at consult to determine whether this is the right fit.

At a glance

Route

SC injection

Dose

1-2 mg

Frequency

1-2x per week

Timing

Any time, consistent day

Cycle

3-6 months

Combining

Stacks well with: Ipamorelin

Avoid combining with: MK-677 (Ibutamoren), CJC-1295 (no DAC)

Safety

Raises GH baseline rather than preserving pulses; water retention possible.

Regulatory: Compounded in the US.

Not appropriate if: cancer-history.

Questions

What does the DAC actually do?⌄

The drug affinity complex lets the peptide bind to albumin in your blood, extending its active life from minutes to days. One or two injections per week can maintain a sustained elevation in GH output rather than single sharp pulses.

How is CJC-1295 with DAC taken?⌄

As a subcutaneous injection of 1-2 mg, once or twice per week, on a consistent day. Timing within the day is flexible - no empty-stomach requirement applies the way it does for shorter-acting GHRHs.

Why would someone choose this over CJC-1295 (no DAC)?⌄

Fewer injections and a more continuous GH baseline. Some people prefer that convenience and consistency. The trade-off is a less pulsatile, more plateau-like effect on GH rather than preserving natural rhythm.

What side effects should I know about?⌄

Water retention is possible because of the sustained GH elevation. This is worth discussing at consult if you are sensitive to that.

Who should not use it?⌄

Anyone with a cancer history is excluded. GH-axis stimulation is contraindicated in that setting regardless of the specific secretagogue.

Can it be combined with CJC-1295 (no DAC)?⌄

No. The two versions should not be combined with each other.

How solid is the evidence behind it?⌄

CJC-1295 with DAC is categorized as emerging evidence - there is real data supporting its mechanism and effects, but the clinical record is less extensive than for sermorelin or tesamorelin.

What sets my actual dose?⌄

Your licensed provider in the PepDepo network at consult. The 1-2 mg range here is for educational orientation. Personalized dosing is set after reviewing your profile and goals.

Want a personalized protocol?

Exact dosing is set with a licensed provider in the PepDepo network. This page is education, not a prescription.

Book a consult

Education only, not medical advice. Peptides discussed are for informational purposes and many are not FDA-approved. Eligibility, prescribing, compounding, and dispensing are handled by appropriately licensed entities. Exact protocols and dosing are set with a licensed provider in the PepDepo network at consult. Content is pending clinical review.